IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.040
-0.145 (-12.24%)
Aug 27, 2026, 10:53 AM EDT - Market open

IN8bio Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-19.2-19.86-29.6-30.34-28.52-14.65
Net Income
-18.67-19.44-30.44-30.01-28.52-14.65
Earnings Per Share
-1.48-4.44-17.05-30.14-40.81-44.09
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
17.9627.0911.1221.2818.1837.02
Total Debt
2.182.785.034.895.872.41
Net Cash (Debt)
15.7824.316.0916.3912.3134.61
Net Cash Growth
56.10%299.18%-62.84%33.16%-64.44%94.23%
Net Cash Per Share
1.255.563.4116.4617.61104.15

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-14.36-12.71-24.15-23.34-24.12-13.51
Capital Expenditures
-0.24--0.19-0.6-3.71-0.31
Free Cash Flow
-14.6-12.71-24.34-23.94-27.83-13.82
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.